US biotech Atalanta Therapeutics has come out of stealth mode backed with $110m from Biogen and Roche ... with Greek mythology from the name of the protein that is targeted by the RNAi drug ...
Biogen has revealed encouraging phase 2 results ... is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their surface. It is thought that CD38-expressing ...
Jan 27 (Reuters) - The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai (4523.T), opens new tab and partner ... deposits of a protein called amyloid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback